Metabolic Health Consequences of Switching to the Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir Plus Lamivudine Regimens in Virologically Suppressed People Living with HIV Aged > 40 Years: A Retrospective Real-World Study

Metabolic Health Consequences of Switching to the Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir Plus Lamivudine Regimens in Virologically Suppressed People Living with HIV Aged > 40 Years: A Retrospective Real-World Study

Jinchuan Shi,1 Wenhui Zhang,1,2 Jie Han,1,2 Zhongdong Zhang,1 Dingyan Yan,1,2 Rongrong Zheng,1 Feng Li,1 Yi Wang1,3 1Department of Infection, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, 310023, People’s Republic of China; 2Department of Nursing, Affiliated Hangz...

Full description

Saved in:
Bibliographic Details
Main Authors: Shi J, Zhang W, Han J, Zhang Z, Yan D, Zheng R, Li F, Wang Y
Format: Article
Language:English
Published: Dove Medical Press 2025-05-01
Series:Infection and Drug Resistance
Subjects:
people living with HIV
virological suppression
antiretroviral therapy
metabolic indices
Online Access:https://www.dovepress.com/metabolic-health-consequences-of-switching-to-the-bictegraviremtricita-peer-reviewed-fulltext-article-IDR
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/metabolic-health-consequences-of-switching-to-the-bictegraviremtricita-peer-reviewed-fulltext-article-IDR

Similar Items